A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 12 Aug 2024
At a glance
- Drugs BL B16D1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 06 Aug 2024 Status changed from not yet recruiting to recruiting.
- 03 Jul 2024 New trial record